Cargando…
Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. METHODS: We performed a s...
Autores principales: | Jiang, Chunguo, Huang, Hui, Liu, Jia, Wang, Yanxun, Lu, Zhiwei, Xu, Zuojun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467250/ https://www.ncbi.nlm.nih.gov/pubmed/23056564 http://dx.doi.org/10.1371/journal.pone.0047024 |
Ejemplares similares
-
Fasudil, a Rho-Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Jiang, Chunguo, et al.
Publicado: (2012) -
Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017) -
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017) -
Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023) -
Imbalance between Th17 and Regulatory T-Cells in Sarcoidosis
por: Huang, Hui, et al.
Publicado: (2013)